Search for a doctor

William V. Bobo, M.D., M.P.H.

Request an Appointment

Publications

  1. Singh B, Parikh SV, Voort JLV, Pazdernik VK, Achtyes ED, Goes FS, Yocum AK, Nykamp L, Becerra A, Smart L, Greden JF, Bobo WV, Frye MA, Burdick KE, Ryan KA. Change in neurocognitive functioning in patients with treatment-resistant depression with serial intravenous ketamine infusions: The Bio-K multicenter trial. Psychiatry Res. 2024 May; 335:115829 Epub 2024 Feb 28
    View PubMed
  2. Parikh SV, Vande Voort JL, Yocum AK, Achtyes E, Goes FS, Nykamp L, Singh B, Lopez-Vives D, Sera CE, Maixner D, Tarnal V, Severe J, Bartek S, Tye SJ, Rico J, Stoppel CJ, Becerra A, Smart L, Miller CR, Frye MA, Greden JF, Bobo WV. Clinical outcomes in the biomarkers of ketamine (Bio-K) study of open-label IV ketamine for refractory depression. J Affect Disord. 2024 Mar 1; 348:143-151 Epub 2023 Dec 22
    View PubMed
  3. Wilton AR, Sheffield K, Wilkes Q, Chesak S, Pacyna J, Sharp R, Croarkin PE, Chauhan M, Dyrbye LN, Bobo WV, Athreya AP. The Burnout PRedictiOn Using Wearable aNd ArtIficial IntelligEnce (BROWNIE) study: a decentralized digital health protocol to predict burnout in registered nurses. BMC Nurs. 2024 Feb 13; 23 (1):114
    View PubMed
  4. Deshpande AJ, Bhandarkar A, Bobo WV, Bydon M, Niazi S, McLaughlin S. Examining the relationship between severe persistent mental illness and surgical outcomes in women undergoing mastectomy for breast cancer. Am J Surg 2023 Jul; 226 (1):4-10 Epub 2022 Dec 28
    View PubMed
  5. Brown LC, Bobo WV, Gall CA, Muller DJ, Bousman CA. Pharmacomicrobiomics of Antidepressants in Depression: A Systematic Review. J Pers Med. 2023 Jun 30; 13 (7) Epub 2023 June 30
    View PubMed
  6. Brumbaugh JE, Ball CT, Crook JE, Stoppel CJ, Carey WA, Bobo WV. Poor Neonatal Adaptation After Antidepressant Exposure During the Third Trimester in a Geographically Defined Cohort. Mayo Clin Proc Innov Qual Outcomes. 2023 Apr; 7 (2):127-139 Epub 2023 Mar 07
    View PubMed
  7. Na PJ, Yaramala SR, Kim JA, Kim H, Goes FS, Zandi PP, Vande Voort JL, Sutor B, Croarkin PE, Bobo WV. Corrigendum to "The PHQ-9 item 9 based screening for suicide risk: A validation study of the patient health questionnaire (PHQ)-9 item 9 with the Columbia suicide severity rating scale (C-SSRS)" [J. Affect. Disord. 232 (2018) 34-40]. J Affect Disord. 2023 Feb 15; 323:900 Epub 2022 Dec 08
    View PubMed
  8. Grossardt BR, Chamberlain AM, Boyd CM, Bobo WV, St Sauver JL, Rocca WA. Convergence of four measures of multi-morbidity. J Multimorb Comorb. 2023 Jan-Dec; 13:26335565221150124 Epub 2023 Jan 02
    View PubMed
  9. Athreya AP, Vande Voort JL, Shekunov J, Rackley SJ, Leffler JM, McKean AJ, Romanowicz M, Kennard BD, Emslie GJ, Mayes T, Trivedi M, Wang L, Weinshilboum RM, Bobo WV, Croarkin PE. Evidence for machine learning guided early prediction of acute outcomes in the treatment of depressed children and adolescents with antidepressants. J Child Psychol Psychiatry. 2022 Nov; 63 (11):1347-1358 Epub 2022 Mar 15
    View PubMed
  10. Bobo WV, Van Ommeren B, Athreya AP. Machine learning, pharmacogenomics, and clinical psychiatry: predicting antidepressant response in patients with major depressive disorder. Expert Rev Clin Pharmacol. 2022 Aug; 15 (8):927-944 Epub 2022 Aug 21
    View PubMed
  11. Zhang C, Virani S, Mayes T, Carmody T, Croarkin PE, Weinshilboum R, Rush AJ, Trivedi M, Athreya AP, Bobo WV. Toward a Definition of "No Meaningful Benefit" From Antidepressant Treatment: An Equipercentile Analysis With Cross-Trial Validation Across Multiple Rating Scales. J Clin Psychiatry. 2022 Jun 27; 83 (4) Epub 2022 June 27
    View PubMed
  12. Zhang CY, Voort JLV, Yuruk D, Mills JA, Emslie GJ, Kennard BD, Mayes T, Trivedi M, Bobo WV, Strawn JR, Athreya AP, Croarkin PE. A Characterization of the Clinical Global Impression Scale Thresholds in the Treatment of Adolescent Depression Across Multiple Rating Scales. J Child Adolesc Psychopharmacol. 2022 Jun; 32 (5):278-287
    View PubMed
  13. Bobo WV, Grossardt BR, Virani S, St Sauver JL, Boyd CM, Rocca WA. Association of Depression and Anxiety With the Accumulation of Chronic Conditions. JAMA Netw Open. 2022 May 2; 5 (5):e229817 Epub 2022 May 02
    View PubMed
  14. Singh B, Kung S, Schak KM, Bobo WV, Frye MA, Vande Voort JL. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Real-World Setting Among Patients with Treatment Refractory Depression. CNS Spectr. 2022 Apr; 27 (2):232
    View PubMed
  15. Grant CW, Barreto EF, Kumar R, Kaddurah-Daouk R, Skime M, Mayes T, Carmody T, Biernacka J, Wang L, Weinshilboum R, Trivedi MH, Bobo WV, Croarkin PE, Athreya AP. Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder. J Pers Med. 2022 Mar 6; 12 (3) Epub 2022 Mar 06
    View PubMed
  16. Simeone RM, Downing KF, Bobo WV, Grosse SD, Khanna AD, Farr SL. Post-traumatic stress disorder, anxiety, and depression among adults with congenital heart defects. Birth Defects Res. 2022 Feb; 114 (3-4):124-135 Epub 2021 Dec 21
    View PubMed
  17. Markota M, Croarkin PE, Bobo WV. Positive Urine Drug Screens and External Mortality in Teenagers Who Present for Medical Care. J Clin Psychiatry. 2022 Jan 11; 83 (1)
    View PubMed
  18. Grant CW, Wilton AR, Kaddurah-Daouk R, Skime M, Biernacka J, Mayes T, Carmody T, Wang L, Lazaridis K, Weinshilboum R, Bobo WV, Trivedi MH, Croarkin PE, Athreya AP. Network science approach elucidates integrative genomic-metabolomic signature of antidepressant response and lifetime history of attempted suicide in adults with major depressive disorder. Front Pharmacol. 2022; 13:984383 Epub 2022 Oct 03
    View PubMed
  19. Chauhan M, Parry R, Bobo WV. Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice. Neuropsychiatr Dis Treat. 2022; 18:1175-1193 Epub 2022 June 14
    View PubMed
  20. Markota M, Coombes BJ, Bieber ED, Kirchoff RW, Bobo WV, Croarkin PE. Relative Age Effect on Problematic Alcohol Use in Adolescents. J Child Adolesc Psychopharmacol. 2021 Dec; 31 (10):692-696 Epub 2021 July 27
    View PubMed
  21. Joyce JB, Grant CW, Liu D, MahmoudianDehkordi S, Kaddurah-Daouk R, Skime M, Biernacka J, Frye MA, Mayes T, Carmody T, Croarkin PE, Wang L, Weinshilboum R, Bobo WV, Trivedi MH, Athreya AP. Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication. Transl Psychiatry. 2021 Oct 7; 11 (1):513 Epub 2021 Oct 07
    View PubMed
  22. Summers AD, Anderson KN, Ailes EC, Grosse SD, Bobo WV, Tepper NK, Reefhuis J. Venlafaxine prescription claims among insured women of reproductive age and pregnant women, 2011-2016. Birth Defects Res. 2021 Aug 15; 113 (14):1052-1056 Epub 2021 Apr 16
    View PubMed
  23. Kamali M, Pegg S, Janos JA, Bobo WV, Brody B, Gao K, Ketter TA, McElroy SL, McInnis MG, Rabideau DJ, Reilly-Harrington NA, Shelton RC, Sylvia LG, Tohen M, Nierenberg A. Illness stage and predominant polarity in bipolar disorder: Correlation with burden of illness and moderation of treatment outcome. J Psychiatr Res. 2021 Aug; 140:205-213 Epub 2021 June 02
    View PubMed
  24. Athreya AP, Bruckl T, Binder EB, John Rush A, Biernacka J, Frye MA, Neavin D, Skime M, Monrad D, Iyer RK, Mayes T, Trivedi M, Carter RE, Wang L, Weinshilboum RM, Croarkin PE, Bobo WV. Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings. Neuropsychopharmacology. 2021 Jun; 46 (7):1272-1282 Epub 2021 Jan 15
    View PubMed
  25. Parikh SV, Lopez D, Vande Voort JL, Rico J, Achtyes E, Coryell W, Goddard A, Goes F, Greden JF, Singh B, Kaplin A, Frye MA, Maixner D, Watson B, Drake K, Tarnal V, Riva-Posse P, Bobo WV, Bio-K Study Team Team. Developing an IV Ketamine Clinic for Treatment-Resistant Depression: a Primer. Psychopharmacol Bull. 2021 Jun 1; 51 (3):109-124
    View PubMed
  26. St Sauver JL, Chamberlain AM, Bobo WV, Boyd CM, Finney Rutten LJ, Jacobson DJ, McGree ME, Grossardt BR, Rocca WA. Implementing the US Department of Health and Human Services definition of multimorbidity: a comparison between billing codes and medical record review in a population-based sample of persons 40-84 years old. BMJ Open. 2021 Apr 24; 11 (4):e042870
    View PubMed
  27. Rocca WA, Grossardt BR, Boyd CM, Chamberlain AM, Bobo WV, St Sauver JL. Multimorbidity, ageing and mortality: normative data and cohort study in an American population. BMJ Open. 2021 Mar 19; 11 (3):e042633
    View PubMed
  28. Anderson KN, Lind JN, Simeone RM, Bobo WV, Mitchell AA, Riehle-Colarusso T, Polen KN, Reefhuis J. Maternal Use of Specific Antidepressant Medications During Early Pregnancy and the Risk of Selected Birth Defects. JAMA Psychiatry. 2020 Dec 1; 77 (12):1246-1255
    View PubMed
  29. Gentry MT, Atherton PJ, Lapid M, Rosen PS, Kung S, Richardson J, Niazi SK, Bobo WV, Clark MM, Rummans TA. Effects of a multidisciplinary quality of life intervention on sleep quality in patients with advanced cancer receiving radiation therapy. Palliat Support Care. 2020 Jun; 18 (3):307-313
    View PubMed
  30. Pettersson D, Gissler M, Hallgren J, Osby U, Westman J, Bobo WV. The overall and sex- and age-group specific incidence rates of cancer in people with schizophrenia: a population-based cohort study. Epidemiol Psychiatr Sci. 2020 May 28; 29:e132
    View PubMed
  31. Yaramala SR, McElroy SL, Geske J, Winham S, Gao K, Reilly-Harrington NA, Ketter TA, Deckersbach T, Kinrys G, Kamali M, Sylvia LG, McInnis MG, Friedman ES, Thase ME, Kocsis JH, Tohen M, Calabrese JR, Bowden CL, Shelton RC, Nierenberg AA, Bobo WV. The impact of binge eating behavior on lithium- and quetiapine-associated changes in body weight, body mass index, and waist circumference during 6 months of treatment: Findings from the bipolar CHOICE study. J Affect Disord. 2020 Apr 1; 266:772-781 Epub 2018 Sept 12
    View PubMed
  32. Bobo WV, Riva-Posse P, Goes FS, Parikh SV. Next-Step Treatment Considerations for Patients With Treatment-Resistant Depression That Responds to Low-Dose Intravenous Ketamine. Focus (Am Psychiatr Publ). 2020 Apr; 18 (2):181-192 Epub 2020 Apr 23
    View PubMed
  33. Ahmed AT, MahmoudianDehkordi S, Bhattacharyya S, Arnold M, Liu D, Neavin D, Moseley MA, Thompson JW, Williams LSJ, Louie G, Skime MK, Wang L, Riva-Posse P, McDonald WM, Bobo WV, Craighead WE, Krishnan R, Weinshilboum RM, Dunlop BW, Millington DS, Rush AJ, Frye MA, Kaddurah-Daouk R, Mood Disorders Precision Medicine Consortium (MDPMC). Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes. J Affect Disord. 2020 Mar 1; 264:90-97 Epub 2019 Nov 30
    View PubMed
  34. Anderson KN, Ailes EC, Lind JN, Broussard CS, Bitsko RH, Friedman JM, Bobo WV, Reefhuis J, Tinker SC, National Birth Defects Prevention Study. Atypical antipsychotic use during pregnancy and birth defect risk: National Birth Defects Prevention Study, 1997-2011. Schizophr Res. 2020 Jan; 215:81-88 Epub 2019 Nov 21
    View PubMed
  35. Bobo WV, Ryu E, Petterson TM, Lackore K, Cheng Y, Liu H, Suarez L, Preisig M, Cooper LT, Roger VL, Pathak J, Chamberlain AM. Bi-directional association between depression and HF: An electronic health records-based cohort study. J Comorb. 2020 Jan-Dec; 10:2235042X20984059 Epub 2020 Dec 24
    View PubMed
  36. Kamali M, Reilly-Harrington NA, Chang WC, McInnis M, McElroy SL, Ketter TA, Shelton RC, Deckersbach T, Tohen M, Kocsis JH, Calabrese JR, Gao K, Thase ME, Bowden CL, Kinrys G, Bobo WV, Brody BD, Sylvia LG, Rabideau DJ, Nierenberg AA. Bipolar depression and suicidal ideation: Moderators and mediators of a complex relationship. J Affect Disord. 2019 Dec 1; 259:164-172 Epub 2019 Aug 19
    View PubMed
  37. Frye MA, Coombes BJ, McElroy SL, Jones-Brando L, Bond DJ, Veldic M, Romo-Nava F, Bobo WV, Singh B, Colby C, Skime MK, Biernacka JM, Yolken R. Association of Cytomegalovirus and Toxoplasma gondii Antibody Titers With Bipolar Disorder. JAMA Psychiatry. 2019 Dec 1; 76 (12):1285-1293
    View PubMed
  38. Gazzuola Rocca L, Smith CY, Bobo WV, Grossardt BR, Stewart EA, Laughlin-Tommaso SK, Rocca WA. Mental health conditions diagnosed before bilateral oophorectomy: a population-based case-control study. Menopause. 2019 Dec; 26 (12):1395-1404
    View PubMed
  39. Singh B, Bobo WV, Rasmussen KG, Stoppel CJ, Rico JA Jr, Schak KM, Biernacka JM, Frye MA, Vande Voort JL. The Association Between Body Mass Index and Remission Rates in Patients With Treatment-Resistant Depression Who Received Intravenous Ketamine. J Clin Psychiatry 2019 Nov 12; 80 (6)
    View PubMed
  40. Fung VC, Overhage LN, Sylvia LG, Reilly-Harrington NA, Kamali M, Gao K, Shelton RC, Ketter TA, Bobo WV, Thase ME, Calabrese JR, Tohen M, Deckersbach T, Nierenberg AA. Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors. J Affect Disord. 2019 Oct 1; 257:17-22 Epub 2019 July 02
    View PubMed
  41. Athreya AP, Neavin D, Carrillo-Roa T, Skime M, Biernacka J, Frye MA, Rush AJ, Wang L, Binder EB, Iyer RK, Weinshilboum RM, Bobo WV. Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication. Clin Pharmacol Ther. 2019 Oct; 106 (4):855-865 Epub 2019 June 29
    View PubMed
  42. Behrendt-Moller I, Madsen T, Sorensen HJ, Sylvia L, Friedman ES, Shelton RC, Bowden CL, Calabrese JR, McElroy SL, Ketter TA, Reilly-Harrington NA, Gao K, Thase M, V Bobo W, Tohen M, McInnis M, Kamali M, Kocsis JH, Deckersbach T, Kohler-Forsberg O, Nierenberg AA. Patterns of changes in bipolar depressive symptoms revealed by trajectory analysis among 482 patients with bipolar disorder. Bipolar Disord. 2019 Jun; 21 (4):350-360 Epub 2018 Dec 01
    View PubMed
  43. Ahmed AT, Biernacka JM, Jenkins G, Rush AJ, Shinozaki G, Veldic M, Kung S, Bobo WV, Hall-Flavin DK, Weinshilboum RM, Wang L, Frye MA. Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure. J Affect Disord. 2019 Mar 1; 246:62-68 Epub 2018 Dec 17
    View PubMed
  44. Kinrys G, Bowden CL, Nierenberg AA, Hearing CM, Gold AK, Rabideau DJ, Sylvia LG, Gao K, Kamali M, Bobo WV, Tohen M, Deckersbach T, McElroy SL, Ketter TA, Shelton RC, Friedman ES, Calabrese JR, McInnis MG, Kocsis J, Thase ME, Singh V, Reilly-Harrington NA. Comorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale. J Affect Disord. 2019 Mar 1; 246:126-131 Epub 2018 Dec 18
    View PubMed
  45. Winham SJ, Bobo WV, Liu J, Coombes B, Backlund L, Frye MA, Biernacka JM, Schalling M, Lavebratt C. Sex-specific effects of gain-of-function P2RX7 variation on bipolar disorder. J Affect Disord. 2019 Feb 15; 245:597-601 Epub 2018 Nov 03
    View PubMed
  46. Bobo WV, Grossardt BR, Lapid MI, Leung JG, Stoppel C, Takahashi PY, Hoel RW, Chang Z, Lachner C, Chauhan M, Flowers L, Brue SM, Frye MA, St Sauver J, Rocca WA, Sutor B. Frequency and predictors of the potential overprescribing of antidepressants in elderly residents of a geographically defined U.S. population. Pharmacol Res Perspect. 2019 Feb; 7 (1):e00461 Epub 2019 Jan 23
    View PubMed
  47. Maki PM, Kornstein SG, Joffe H, Bromberger JT, Freeman EW, Athappilly G, Bobo WV, Rubin LH, Koleva HK, Cohen LS, Soares CN. Guidelines for the Evaluation and Treatment of Perimenopausal Depression: Summary and Recommendations. J Womens Health (Larchmt). 2019 Feb; 28 (2):117-134 Epub 2018 Sept 05
    View PubMed
  48. Amare AT, Schubert KO, Tekola-Ayele F, Hsu YH, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmoller J, Chen CH, Domschke K, Hall-Flavin DK, Hong CJ, Illi A, Ji Y, Kampman O, Kinoshita T, Leinonen E, Liou YJ, Mushiroda T, Nonen S, Skime MK, Wang L, Kato M, Liu YL, Praphanphoj V, Stingl JC, Bobo WV, Tsai SJ, Kubo M, Klein TE, Weinshilboum RM, Biernacka JM, Baune BT. The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression. J Neural Transm (Vienna). 2019 Jan; 126 (1):35-45 Epub 2019 Jan 04
    View PubMed
  49. Veldic M, Ahmed AT, Blacker CJ, Geske JR, Biernacka JM, Borreggine KL, Moore KM, Prieto ML, Vande Voort JL, Croarkin PE, Hoberg AA, Kung S, Alarcon RD, Keeth N, Singh B, Bobo WV, Frye MA. Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications. Front Pharmacol. 2019; 10:83 Epub 2019 Feb 19
    View PubMed
  50. Westman J, Eriksson SV, Gissler M, Hallgren J, Prieto ML, Bobo WV, Frye MA, Erlinge D, Alfredsson L, Osby U. Increased cardiovascular mortality in people with schizophrenia: a 24-year national register study. Epidemiol Psychiatr Sci. 2018 Oct; 27 (5):519-527 Epub 2017 June 05
    View PubMed
  51. Ahmed AT, Frye MA, Rush AJ, Biernacka JM, Craighead WE, McDonald WM, Bobo WV, Riva-Posse P, Tye SJ, Mayberg HS, Hall-Flavin DK, Skime MK, Jenkins GD, Wang L, Krishnan RR, Weinshilboum RM, Kaddurah-Daouk R, Dunlop BW, Mood Disorders Precision Medicine Consortium (MDPMC). Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders. J Affect Disord. 2018 Oct 1; 238:1-7 Epub 2018 May 26
    View PubMed
  52. Maki PM, Kornstein SG, Joffe H, Bromberger JT, Freeman EW, Athappilly G, Bobo WV, Rubin LH, Koleva HK, Cohen LS, Soares CN, Board of Trustees for The North American Menopause Society (NAMS) and the Women and Mood Disorders Task Force of the National Network of Depression Centers. Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Menopause. 2018 Oct; 25 (10):1069-1085
    View PubMed
  53. Caldieraro MA, Walsh S, Deckersbach T, Bobo WV, Gao K, Ketter TA, Shelton RC, Reilly-Harrington NA, Tohen M, Calabrese JR, Thase ME, Kocsis JH, Sylvia LG, Nierenberg AA. Decreased activation and subsyndromal manic symptoms predict lower remission rates in bipolar depression. Aust N Z J Psychiatry. 2018 Oct; 52 (10):994-1002 Epub 2017 Nov 16
    View PubMed
  54. Markota M, Coombes BJ, Larrabee BR, McElroy SL, Bond DJ, Veldic M, Colby CL, Chauhan M, Cuellar-Barboza AB, Fuentes M, Kung S, Prieto ML, Rummans TA, Bobo WV, Frye MA, Biernacka JM. Association of schizophrenia polygenic risk score with manic and depressive psychosis in bipolar disorder. Transl Psychiatry. 2018 Sep 10; 8 (1):188 Epub 2018 Sept 10
    View PubMed
  55. Athreya A, Iyer R, Neavin D, Wang L, Weinshilboum R, Kaddurah-Daouk R, Rush J, Frye M, Bobo W. Augmentation of Physician Assessments with Multi-Omics Enhances Predictability of Drug Response: A Case Study of Major Depressive Disorder. IEEE Comput Intell Mag. 2018 Aug; 13 (3):20-31 Epub 2018 July 20
    View PubMed
  56. Na PJ, Yaramala SR, Kim JA, Kim H, Goes FS, Zandi PP, Vande Voort JL, Sutor B, Croarkin P, Bobo WV. The PHQ-9 Item 9 based screening for suicide risk: a validation study of the Patient Health Questionnaire (PHQ)-9 Item 9 with the Columbia Suicide Severity Rating Scale (C-SSRS). J Affect Disord. 2018 May; 232:34-40 Epub 2018 Feb 17
    View PubMed
  57. Caldieraro MA, Dufour S, Sylvia LG, Gao K, Ketter TA, Bobo WV, Walsh S, Janos J, Tohen M, Reilly-Harrington NA, McElroy SL, Shelton RC, Bowden CL, Deckersbach T, Nierenberg AA. Treatment outcomes of acute bipolar depressive episode with psychosis. Depress Anxiety. 2018 May; 35 (5):402-410 Epub 2018 Jan 12
    View PubMed
  58. Campolong K, Jenkins S, Clark MM, Borowski K, Nelson N, Moore KM, Bobo WV. The association of exercise during pregnancy with trimester-specific and postpartum quality of life and depressive symptoms in a cohort of healthy pregnant women. Arch Womens Ment Health. 2018 Apr; 21 (2):215-224 Epub 2017 Oct 24
    View PubMed
  59. Liu D, Ray B, Neavin DR, Zhang J, Athreya AP, Biernacka JM, Bobo WV, Hall-Flavin DK, Skime MK, Zhu H, Jenkins GD, Batzler A, Kalari KR, Boakye-Agyeman F, Matson WR, Bhasin SS, Mushiroda T, Nakamura Y, Kubo M, Iyer RK, Wang L, Frye MA, Kaddurah-Daouk R, Weinshilboum RM. Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics. Transl Psychiatry. 2018 Jan 10; 8 (1):10
    View PubMed
  60. Amare AT, Schubert KO, Tekola-Ayele F, Hsu YH, Sangkuhl K, Jenkins G, Whaley RM, Barman P, Batzler A, Altman RB, Arolt V, Brockmoller J, Chen CH, Domschke K, Hall-Flavin DK, Hong CJ, Illi A, Ji Y, Kampman O, Kinoshita T, Leinonen E, Liou YJ, Mushiroda T, Nonen S, Skime MK, Wang L, Kato M, Liu YL, Praphanphoj V, Stingl JC, Bobo WV, Tsai SJ, Kubo M, Klein TE, Weinshilboum RM, Biernacka JM, Baune BT. Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder. Front Psychiatry. 2018; 9:65 Epub 2018 Mar 06
    View PubMed
  61. Tohen M, Gold AK, Sylvia LG, Montana RE, McElroy SL, Thase ME, Rabideau DJ, Nierenberg AA, Reilly-Harrington NA, Friedman ES, Shelton RC, Bowden CL, Singh V, Deckersbach T, Ketter TA, Calabrese JR, Bobo WV, McInnis MG. Corrigendum to bipolar mixed features - Results from the comparative effectiveness for bipolar disorder (Bipolar CHOICE) study [Journal of Affective Disorders 217 (2017) 183-189]. J Affect Disord. 2018 Jan 1; 225:775-777 Epub 2017 Aug 18
    View PubMed
  62. Sylvia LG, Chang WC, Kamali M, Tohen M, Kinrys G, Deckersbach T, Calabrese JR, Thase ME, Reilly-Harrington N, Bobo WV, Kocsis JH, McInnis MG, Bowden CL, Ketter TA, Friedman ES, Shelton RC, McElroy SL, Gao K, Rabideau DJ, Nierenberg AA. Sleep disturbance may impact treatment outcome in bipolar disorder: A preliminary investigation in the context of a large comparative effectiveness trial. J Affect Disord. 2018 Jan 1; 225:563-568 Epub 2017 Aug 19
    View PubMed
  63. Bobo WV, Na PJ, Geske JR, McElroy SL, Frye MA, Biernacka JM. The relative influence of individual risk factors for attempted suicide in patients with bipolar I versus bipolar II disorder. J Affect Disord. 2018 Jan 1; 225:489-494 Epub 2017 Aug 30
    View PubMed
  64. Kohler-Forsberg O, Madsen T, Behrendt-Moller I, Sylvia L, Bowden CL, Gao K, Bobo WV, Trivedi MH, Calabrese JR, Thase M, Shelton RC, McInnis M, Tohen M, Ketter TA, Friedman ES, Deckersbach T, McElroy SL, Reilly-Harrington NA, Nierenberg AA. Trajectories of suicidal ideation over 6 months among 482 outpatients with bipolar disorder. J Affect Disord. 2017 Dec 1; 223:146-152 Epub 2017 July 20
    View PubMed
  65. Bobo WV. The Diagnosis and Management of Bipolar I and II Disorders: Clinical Practice Update. Mayo Clin Proc. 2017 Oct; 92 (10):1532-1551 Epub 2017 Sept 06
    View PubMed
  66. Caldieraro MA, Sylvia LG, Dufour S, Walsh S, Janos J, Rabideau DJ, Kamali M, McInnis MG, Bobo WV, Friedman ES, Gao K, Tohen M, Reilly-Harrington NA, Ketter TA, Calabrese JR, McElroy SL, Thase ME, Shelton RC, Bowden CL, Kocsis JH, Deckersbach T, Nierenberg AA. Clinical correlates of acute bipolar depressive episode with psychosis. J Affect Disord. 2017 Aug 1; 217:29-33 Epub 2017 Mar 30
    View PubMed
  67. Tohen M, Gold AK, Sylvia LG, Montana RE, McElroy SL, Thase ME, Rabideau DJ, Nierenberg AA, Reilly-Harrington NA, Friedman ES, Shelton RC, Bowden CL, Singh V, Deckersbach T, Ketter TA, Calabrese JR, Bobo WV, McInnis MG. Bipolar mixed features - Results from the comparative effectiveness for bipolar disorder (Bipolar CHOICE) study. J Affect Disord. 2017 Aug 1; 217:183-189 Epub 2017 Apr 05
    View PubMed
  68. Lee S, Herrin J, Bobo WV, Johnson R, Sangaralingham LR, Campbell RL. Predictors of Return Visits Among Insured Emergency Department Mental Health and Substance Abuse Patients, 2005-2013. West J Emerg Med. 2017 Aug; 18 (5):884-893 Epub 2017 July 17
    View PubMed
  69. Mischoulon D, Shelton RC, Baer L, Bobo WV, Curren L, Fava M, Papakostas GI. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychiatry. 2017 Apr; 78 (4):449-455
    View PubMed
  70. Athreya AP, Banerjee SS, Neavin D, Kaddurah-Daouk R, Rush AJ, Frye MA, Wang L, Weinshilboum RM, Bobo WV, Iyer RK. Data-driven longitudinal modeling and prediction of symptom dynamics in major depressive disorder: Integrating factor graphs and learning methods 2017 IEEE Conference on Computational Intelligence in Bioinformatics and Computational Biology, CIBCB 2017. 2017; 8058559
  71. Gupta M, Neavin D, Liu D, Biernacka J, Hall-Flavin D, Bobo WV, Frye MA, Skime M, Jenkins GD, Batzler A, Kalari K, Matson W, Bhasin SS, Zhu H, Mushiroda T, Nakamura Y, Kubo M, Wang L, Kaddurah-Daouk R, Weinshilboum RM. TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics. Mol Psychiatry. 2016 Dec; 21 (12):1717-1725 Epub 2016 Feb 23
    View PubMed
  72. Vande Voort JL, Morgan RJ, Kung S, Rasmussen KG, Rico J, Palmer BA, Schak KM, Tye SJ, Ritter MJ, Frye MA, Bobo WV. Continuation phase intravenous ketamine in adults with treatment-resistant depression. J Affect Disord. 2016 Dec; 206:300-304. Epub 2016 Sep 12.
    View PubMed
  73. Reilly-Harrington NA, Sylvia LG, Rabideau DJ, Gold AK, Deckersbach T, Bowden CL, Bobo WV, Singh V, Calabrese JR, Shelton RC, Friedman ES, Thase ME, Kamali M, Tohen M, McInnis MG, McElroy SL, Ketter TA, Kocsis JH, Kinrys G, Nierenberg AA. Tracking medication changes to assess outcomes in comparative effectiveness research: A bipolar CHOICE study. J Affect Disord. 2016 Nov 15; 205:159-164 Epub 2016 July 05
    View PubMed
  74. Bobo WV, Yawn BP, St Sauver JL, Grossardt BR, Boyd CM, Rocca WA. Prevalence of Combined Somatic and Mental Health Multimorbidity: Patterns by Age, Sex, and Race/Ethnicity. J Gerontol A Biol Sci Med Sci. 2016 Nov; 71 (11):1483-1491 Epub 2016 Mar 02
    View PubMed
  75. McElroy SL, Crow S, Blom TJ, Cuellar-Barboza AB, Prieto ML, Veldic M, Winham SJ, Bobo WV, Geske J, Seymour LR, Mori N, Bond DJ, Biernacka JM, Frye MA. Clinical features of bipolar spectrum with binge eating behaviour. J Affect Disord. 2016 Sep 1; 201:95-8 Epub 2016 May 06
    View PubMed
  76. Leung JG, Nelson S, Cunningham JL, Thompson VH, Bobo WV, Kung S, Dierkhising RA, Plevak MF, Lapid MI. A Single-Dose Crossover Pharmacokinetic Comparison Study of Oral, Rectal and Topical Quetiapine in Healthy Adults. Clin Pharmacokinet. 2016 Aug; 55 (8):971-6
    View PubMed
  77. Bobo WV, Vande Voort JL, Croarkin PE, Leung JG, Tye SJ, Frye MA. KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE. Depress Anxiety. 2016 Aug; 33 (8):698-710 Epub 2016 Apr 06
    View PubMed
  78. Bobo WV, Anglero GC, Jenkins G, Hall-Flavin DK, Weinshilboum R, Biernacka JM. Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data. Hum Psychopharmacol. 2016 May; 31 (3):185-92 Epub 2016 Mar 21
    View PubMed
  79. Ryu E, Chamberlain AM, Pendegraft RS, Petterson TM, Bobo WV, Pathak J. Quantifying the impact of chronic conditions on a diagnosis of major depressive disorder in adults: a cohort study using linked electronic medical records. BMC Psychiatry. 2016 Apr 26; 16:114
    View PubMed
  80. Prieto ML, Schenck LA, Kruse JL, Klaas JP, Chamberlain AM, Bobo WV, Bellivier F, Leboyer M, Roger VL, Brown RD Jr, Rocca WA, Frye MA. Long-term risk of myocardial infarction and stroke in bipolar I disorder: A population-based Cohort Study. J Affect Disord. 2016 Apr; 194:120-7 Epub 2016 Jan 13
    View PubMed
  81. Reilly-Harrington NA, Shelton RC, Kamali M, Rabideau DJ, Shesler LW, Trivedi MH, McElroy SL, Sylvia LG, Bowden CL, Ketter TA, Calabrese JR, Thase ME, Bobo WV, Deckersbach T, Tohen M, McInnis MG, Kocsis JH, Gold AK, Singh V, Finkelstein DM, Kinrys G, Nierenberg AA. A tool to predict suicidal ideation and behavior in bipolar disorder: The Concise Health Risk Tracking Self-Report. J Affect Disord. 2016 Mar 1; 192:212-8 Epub 2015 Dec 30
    View PubMed
  82. McElroy SL, Crow S, Blom TJ, Biernacka JM, Winham SJ, Geske J, Cuellar-Barboza AB, Bobo WV, Prieto ML, Veldic M, Mori N, Seymour LR, Bond DJ, Frye MA. Prevalence and correlates of DSM-5 eating disorders in patients with bipolar disorder. J Affect Disord. 2016 Feb; 191:216-21 Epub 2015 Nov 19
    View PubMed
  83. McElroy SL, Kemp DE, Friedman ES, Reilly-Harrington NA, Sylvia LG, Calabrese JR, Rabideau DJ, Ketter TA, Thase ME, Singh V, Tohen M, Bowden CL, Bernstein EE, Brody BD, Deckersbach T, Kocsis JH, Kinrys G, Bobo WV, Kamali M, McInnis MG, Leon AC, Faraone S, Nierenberg AA, Shelton RC. Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder. Acta Psychiatr Scand. 2016 Feb; 133 (2):144-153 Epub 2015 June 26
    View PubMed
  84. Nierenberg AA, McElroy SL, Friedman ES, Ketter TA, Shelton RC, Deckersbach T, McInnis MG, Bowden CL, Tohen M, Kocsis JH, Calabrese JR, Kinrys G, Bobo WV, Singh V, Kamali M, Kemp D, Brody B, Reilly-Harrington NA, Sylvia LG, Shesler LW, Bernstein EE, Schoenfeld D, Rabideau DJ, Leon AC, Faraone S, Thase ME. Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): a pragmatic 6-month trial of lithium versus quetiapine for bipolar disorder. J Clin Psychiatry. 2016 Jan; 77 (1):90-9
    View PubMed
  85. Deckersbach T, Nierenberg AA, McInnis MG, Salcedo S, Bernstein EE, Kemp DE, Shelton RC, McElroy SL, Sylvia LG, Kocsis JH, Bobo WV, Friedman ES, Singh V, Tohen M, Bowden CL, Ketter TA, Calabrese JR, Thase ME, Reilly-Harrington NA, Rabideau DJ, Kinrys G, Kamali M. Baseline disability and poor functioning in bipolar disorder predict worse outcomes: results from the Bipolar CHOICE study. J Clin Psychiatry. 2016 Jan; 77: (1)100-8.
    View PubMed
  86. Papakostas GI, Fava M, Baer L, Swee MB, Jaeger A, Bobo WV, Shelton RC. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study. Am J Psychiatry. 2015 Dec; 172 (12):1251-8 Epub 2015 June 18
    View PubMed
  87. Erol A, Winham SJ, McElroy SL, Frye MA, Prieto ML, Cuellar-Barboza AB, Fuentes M, Geske J, Mori N, Biernacka JM, Bobo WV. Sex differences in the risk of rapid cycling and other indicators of adverse illness course in patients with bipolar I and II disorder. Bipolar Disord. 2015 Sep; 17 (6):670-6
    View PubMed
  88. Prieto ML, McElroy SL, Hayes SN, Sutor B, Kung S, Bobo WV, Fuentes ME, Cuellar-Barboza AB, Crow S, Osby U, Chauhan M, Westman J, Geske JR, Colby CL, Ryu E, Biernacka JM, Frye MA. Association between history of psychosis and cardiovascular disease in bipolar disorder. Bipolar Disord. 2015 Aug; 17 (5):518-27 Epub 2015 June 09
    View PubMed
  89. Bonaccorso S, Sodhi M, Li J, Bobo WV, Chen Y, Tumuklu M, Theleritis C, Jayathilake K, Meltzer HY. The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia. Bipolar Disord. 2015 Aug; 17 (5):528-35 Epub 2015 Apr 15
    View PubMed
  90. Bobo WV. More evidence of an association between antipsychotic drugs and the risk of diabetes in children and adolescents: a population-based study. Evid Based Ment Health 2015 May; 18 (2):e1 Epub 2015 Mar 05
    View PubMed
  91. Sylvia LG, Thase ME, Reilly-Harrington NA, Salcedo S, Brody B, Kinrys G, Kemp D, Shelton RC, McElroy SL, Kocsis JH, Bobo WV, Kamali M, McInnis M, Friedman E, Tohen M, Bowden CL, Ketter TA, Singh V, Calabrese J, Nierenberg AA, Rabideau DJ, Elson CM, Deckersbach T. Psychotherapy use in bipolar disorder: Association with functioning and illness severity. Aust N Z J Psychiatry. 2015 May; 49: (5)453-61.
    View PubMed
  92. St Sauver JL, Boyd CM, Grossardt BR, Bobo WV, Finney Rutten LJ, Roger VL, Ebbert JO, Therneau TM, Yawn BP, Rocca WA. Risk of developing multimorbidity across all ages in an historical cohort study: differences by sex and ethnicity. BMJ Open. 2015 Feb 3; 5 (2):e006413 Epub 2015 Feb 03
    View PubMed
  93. Bobo WV, Reilly-Harrington NA, Ketter TA, Brody BD, Kinrys G, Kemp DE, Shelton RC, McElroy SL, Sylvia LG, Kocsis JH, McInnis MG, Friedman ES, Singh V, Tohen M, Bowden CL, Deckersbach T, Calabrese JR, Thase ME, Nierenberg AA, Rabideau DJ, Schoenfeld DA, Faraone SV, Kamali M. Complexity of illness and adjunctive benzodiazepine use in outpatients with bipolar I or II disorder: results from the Bipolar CHOICE study. J Clin Psychopharmacol. 2015 Feb; 35 (1):68-74
    View PubMed
  94. Epstein RA, Moore KM, Bobo WV. Treatment of bipolar disorders during pregnancy: maternal and fetal safety and challenges. Drug Healthc Patient Saf. 2015; 7:7-29 Epub 2014 Dec 24
    View PubMed
  95. Kelliny M, Croarkin PE, Moore KM, Bobo WV. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. Ther Clin Risk Manag. 2015; 11:1193-212 Epub 2015 Aug 12
    View PubMed
  96. Sylvia LG, Shelton RC, Kemp DE, Bernstein EE, Friedman ES, Brody BD, Mcelroy SL, Singh V, Tohen M, Bowden CL, Ketter TA, Deckersbach T, Thase ME, Reilly-Harrington NA, Nierenberg AA, Rabideau DJ, Kinrys G, Kocsis JH, Bobo WV, Kamali M, Mcinnis MG, Calabrese JR. Medical burden in bipolar disorder: Findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE). Bipolar Disord. 2015; 17(2):212-23.
    View PubMed
  97. Frye MA, Prieto ML, Bobo WV, Kung S, Veldic M, Alarcon RD, Moore KM, Choi DS, Biernacka JM, Tye SJ. Current landscape, unmet needs, and future directions for treatment of bipolar depression. J Affect Disord. 2014 Dec; 169 Suppl 1:S17-23
    View PubMed
  98. Zhong WJ, Maradit Kremers H, Yawn BP, Bobo WV, St Sauver J, Ebbert JO, Finney Rutten LJ, Jacobson DJ, Brue SM, Rocca WA. Time trends of antidepressant drug prescriptions in men versus women in a geographically defined US population. Archives Of Womens Mental Health. 2014 Dec; 17(6):485-92.
    View PubMed
  99. Prieto ML, Cuellar-Barboza AB, Bobo WV, Roger VL, Bellivier F, Leboyer M, West CP, Frye MA. Risk of myocardial infarction and stroke in bipolar disorder: a systematic review and exploratory meta-analysis. Acta Psychiatr Scand. 2014 Nov; 130 (5):342-53 Epub 2014 May 22
    View PubMed
  100. Rocca WA, Boyd CM, Grossardt BR, Bobo WV, Finney Rutten LJ, Roger VL, Ebbert JO, Therneau TM, Yawn BP, St Sauver JL. Prevalence of multimorbidity in a geographically defined American population: patterns by age, sex, and race/ethnicity. Mayo Clin Proc. 2014 Oct; 89 (10):1336-49 Epub 2014 Sept 11
    View PubMed
  101. Bobo WV, Wollan P, Lewis G, Bertram S, Kurland MJ, Vore K, Yawn BP. Depressive symptoms and access to mental health care in women screened for postpartum depression who lose health insurance coverage after delivery: findings from the Translating Research into Practice for Postpartum Depression (TRIPPD) effectiveness study. Mayo Clin Proc. 2014 Sep; 89 (9):1220-8 Epub 2014 Aug 01
    View PubMed
  102. Bobo WV, Pathak J, Kremers HM, Yawn BP, Brue SM, Stoppel CJ, Croarkin PE, St Sauver J, Frye MA, Rocca WA. An electronic health record driven algorithm to identify incident antidepressant medication users. J Am Med Inform Assoc. 2014 Sep-Oct; 21 (5):785-91 Epub 2014 Apr 29
    View PubMed
  103. Gerhard T, Huybrechts K, Olfson M, Schneeweiss S, Bobo WV, Doraiswamy PM, Devanand DP, Lucas JA, Huang C, Malka ES, Levin R, Crystal S. Comparative mortality risks of antipsychotic medications in community-dwelling older adults. Br J Psychiatry. 2014 Jul; 205(1):44-51. Epub 2013 Aug 08.
    View PubMed
  104. Bobo WV, Reilly-Harrington NA, Ketter TA, Brody BD, Kinrys G, Kemp DE, Shelton RC, McElroy SL, Sylvia LG, Kocsis JH, McInnis MG, Friedman ES, Singh V, Tohen M, Bowden CL, Deckersbach T, Calabrese JR, Thase ME, Nierenberg AA, Rabideau DJ, Schoenfeld DA, Faraone SV, Kamali M. Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: results from the Bipolar CHOICE trial. J Affect Disord. 2014 Jun; 161:30-5 Epub 2014 Mar 13
    View PubMed
  105. Bobo WV, Yawn BP. Concise review for physicians and other clinicians: postpartum depression. Mayo Clin Proc. 2014 Jun; 89 (6):835-44
    View PubMed
  106. Bobo WV, Epstein RA Jr, Hayes RM, Shelton RC, Hartert TV, Mitchel E, Horner J, Wu P. The effect of regulatory advisories on maternal antidepressant prescribing, 1995-2007: an interrupted time series study of 228,876 pregnancies. Arch Womens Ment Health. 2014 Feb; 17 (1):17-26 Epub 2013 Oct 03
    View PubMed
  107. Epstein RA, Moore KM, Bobo WV. Treatment of nonpsychotic major depression during pregnancy: patient safety and challenges. Drug Healthc Patient Saf. 2014; 6:109-29 Epub 2014 Sept 18
    View PubMed
  108. Nierenberg AA, Sylvia LG, Leon AC, Reilly-Harrington NA, Shesler LW, McElroy SL, Friedman ES, Thase ME, Shelton RC, Bowden CL, Tohen M, Singh V, Deckersbach T, Ketter TA, Kocsis JH, McInnis MG, Schoenfeld D, Bobo WV, Calabrese JR, Bipolar CHOICE Study Group. Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar CHOICE): A pragmatic trial of complex treatment for a complex disorder. Clin Trials. 2014; 11(1):114-27. Epub 2013 Dec 17
    View PubMed
  109. Sylvia LG, Friedman ES, Kocsis JH, Bernstein EE, Brody BD, Kinrys G, Kemp DE, Shelton RC, McElroy SL, Bobo WV, Kamali M, McInnis MG, Tohen M, Bowden CL, Ketter TA, Deckersbach T, Calabrese JR, Thase ME, Reilly-Harrington NA, Singh V, Rabideau DJ, Nierenberg AA. Association of exercise with quality of life and mood symptoms in a comparative effectiveness study of bipolar disorder. J Affect Disord. 2013 Nov; 151 (2):722-727 Epub 2013 Aug 16
    View PubMed
  110. Bobo WV, Cooper WO, Stein CM, Olfson M, Graham D, Daugherty J, Fuchs DC, Ray WA. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry. 2013 Oct; 70(10):1067-75.
    View PubMed
  111. Epstein RA, Bobo WV, Martin PR, Morrow JA, Wang W, Chandrasekhar R, Cooper WO. Increasing pregnancy-related use of prescribed opioid analgesics. Ann Epidemiol. 2013 Aug; 23(8):498-503.
    View PubMed
  112. Epstein RA, Bobo WV, Shelton RC, Arbogast PG, Morrow JA, Wang W, Chandrasekhar R, Cooper WO. Increasing use of atypical antipsychotics and anticonvulsants during pregnancy. Pharmacoepidemiol Drug Saf. 2013 Jul; 22(7):794-801. Epub 2012 Nov 05.
    View PubMed
  113. Toh S, Li Q, Cheetham TC, Cooper WO, Davis RL, Dublin S, Hammad TA, Li DK, Pawloski PA, Pinheiro SP, Raebel MA, Scott PE, Smith DH, Bobo WV, Lawrence JM, Dashevsky I, Haffenreffer K, Avalos LA, Andrade SE. Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585,615 deliveries. Arch Womens Ment Health. 2013 Apr; 16(2):149-57. Epub 2013 Feb 07.
    View PubMed
  114. Bobo WV. Switching antipsychotics: Why, when, and how? Psychiatric Times. 2013; 30(3):26-29.
  115. Bobo WV. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013 Jan; 6(1):61-91.
    View PubMed
  116. Jacobowski NL, Heckers S, Bobo WV. Delirious mania: detection, diagnosis, and clinical management in the acute setting. J Psychiatr Pract. 2013 Jan; 19(1):15-28.
    View PubMed
  117. Bobo WV, Davis RL, Toh S, Li DK, Andrade SE, Cheetham TC, Pawloski P, Dublin S, Pinheiro S, Hammad T, Scott PE, Epstein RA Jr, Arbogast PG, Morrow JA, Dudley JA, Lawrence JM, Avalos LA, Cooper WO. Trends in the use of antiepileptic drugs among pregnant women in the US, 2001-2007: a medication exposure in pregnancy risk evaluation program study. Paediatr Perinat Epidemiol. 2012 Nov; 26(6):578-88.
    View PubMed
  118. Chen Y, Bobo WV, Watts K, Jayathilake K, Tang T, Meltzer HY. Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study. J Psychopharmacol. 2012 Sep; 26(9):1201-10. Epub 2012 Jan 09.
    View PubMed
  119. Olfson M, Gerhard T, Huang C, Lieberman JA, Bobo WV, Crystal S. Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia. Schizophr Bull. 2012 Jun; 38(4):845-53. Epub 2011 Feb 09.
    View PubMed
  120. Bobo WV, Cooper WO, Stein CM, Olfson M, Mounsey J, Daugherty J, Ray WA. Positive predictive value of a case definition for diabetes mellitus using automated administrative health data in children and youth exposed to antipsychotic drugs or control medications: a Tennessee Medicaid study. BMC Med Res Methodol. 2012; 12:128. Epub 2012 Aug 24.
    View PubMed
  121. Epstein RA, Feix J, Arbogast PG, Beckjord SH, Bobo WV. Changes to the financial responsibility for juvenile court ordered psychiatric evaluations reduce inpatient services utilization: an interrupted time series study. BMC Health Serv Res. 2012; 12:136. Epub 2012 May 30.
    View PubMed
  122. Meltzer HY, Bonaccorso S, Bobo WV, Chen Y, Jayathilake K. A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. J Clin Psychiatry. 2011 Dec; 72(12):1602-10. Epub 2011 Jul 12.
    View PubMed
  123. Bobo WV, Epstein RA, Lynch A, Patton TD, Bossaller NA, Shelton RC. A randomized open comparison of long-acting injectable risperidone and treatment as usual for prevention of relapse, rehospitalization, and urgent care referral in community-treated patients with rapid cycling bipolar disorder. Clin Neuropharmacol. 2011 Nov-Dec; 34(6):224-33.
    View PubMed
  124. Bobo WV, Chen H, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, Warden D, Morris DW, Luther JF, Husain MM, Cook IA, Lesser IM, Kornstein SG, Wisniewski SR, Rush AJ, Shelton RC. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. J Affect Disord. 2011 Oct; 133(3):467-76. Epub 2011 May 23.
    View PubMed
  125. Bobo WV, Bonaccorso S, Jayathilake K, Meltzer HY. Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder. Psychiatry Res. 2011 Sep 30; 189(2):200-7. Epub 2011 Jul 28.
    View PubMed
  126. Bobo WV, Epstein RA Jr, Shelton RC. Effects of orally disintegrating vs regular olanzapine tablets on body weight, eating behavior, glycemic and lipid indices, and gastrointestinal hormones: a randomized, open comparison in outpatients with bipolar depression. Ann Clin Psychiatry. 2011 Aug; 23(3):193-201.
    View PubMed
  127. Bobo WV, Woodward ND, Sim MY, Jayathilake K, Meltzer HY. The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: a randomized, double-blind, placebo-controlled trial. Schizophr Res. 2011 Aug; 130(1-3):106-13. Epub 2011 Jun 08.
    View PubMed
  128. Epstein RA, Bobo WV, Cull MJ, Gatlin D. Sleep and school problems among children and adolescents in state custody. J Nerv Ment Dis. 2011 Apr; 199(4):251-6.
    View PubMed
  129. Ramsey TL, Meltzer HY, Brock GN, Mehrotra B, Jayathilake K, Bobo WV, Brennan MD. Evidence for a SULT4A1 haplotype correlating with baseline psychopathology and atypical antipsychotic response. Pharmacogenomics. 2011 Apr; 12(4):471-80.
    View PubMed
  130. Bobo WV, Cooper WO, Epstein RA Jr, Arbogast PG, Mounsey J, Ray WA. Positive predictive value of automated database records for diabetic ketoacidosis (DKA) in children and youth exposed to antipsychotic drugs or control medications: a Tennessee Medicaid Study. BMC Med Res Methodol. 2011; 11:157. Epub 2011 Nov 23.
    View PubMed
  131. Bobo WV, Shelton RC. Risperidone long-acting injectable (Risperdal Consta(R)) for maintenance treatment in patients with bipolar disorder. Expert Rev Neurother. 2010 Nov; 10(11):1637-58.
    View PubMed
  132. Meltzer HY, Bobo WV, Lee MA, Cola P, Jayathilake K. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. Psychiatry Res. 2010 May 30; 177(3):286-93. Epub 2010 Apr 08.
    View PubMed
  133. Bobo WV, Shelton RC. Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression. Expert Rev Neurother. 2010 May; 10(5):651-70.
    View PubMed
  134. Bobo WV, Jayathilake K, Lee MA, Meltzer HY. Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics. Psychiatry Res. 2010 Apr 30; 176(2-3):114-9. Epub 2010 Mar 02.
    View PubMed
  135. Bobo WV, Shelton RC. L-methylfolate (Deplin) for depression. Med Lett Drugs Ther. 2010 Apr 19; 52(1336):31-2.
    View PubMed
  136. Bobo WV, Stovall JA, Knostman M, Koestner J, Shelton RC. Converting from brand-name to generic clozapine: a review of effectiveness and tolerability data. Am J Health Syst Pharm. 2010 Jan 1; 67(1):27-37.
    View PubMed
  137. Bobo WV, Epstein RA, Shelton RC. Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8-week open label trial. Hum Psychopharmacol. 2010 Jan; 25(1):30-6.
    View PubMed
  138. Bobo WV, Epstein RA Jr, Shelton RC. Acute bipolar depression: a review of the use of olanzapine/fluoxetine. Clinical Medicine Insights Therapeutics. 2010; 2:825-840.
  139. Bobo WV, Shelton RC. Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data. Expert Opin Pharmacother. 2009 Sep; 10(13):2145-59.
    View PubMed
  140. Bobo WV, Jayathilake K, Lee MA, Meltzer HY. Melperone, an aytpical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neuroleptics. Hum Psychopharmacol. 2009 Jul; 24(5):415-22.
    View PubMed
  141. Bobo WV, Murphy MJ, Heckers SH. Recurring episodes of Bell's mania after cerebrovascular accident. Psychosomatics. 2009 May-Jun; 50(3):285-8.
    View PubMed
  142. Bobo WV, Nevin R, Greene E, Lacy TJ. The effect of psychiatric third-year rotation setting on academic performance, student attitudes, and specialty choice. Acad Psychiatry. 2009 Mar-Apr; 33(2):105-11.
    View PubMed
  143. Bobo WV, Shelton RC. Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues. Neuropsychiatr Dis Treat. 2009; 5:369-83. Epub 2009 Jul 02.
    View PubMed
  144. Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, Eerdekens M. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry. 2008 May; 69(5):817-29.
    View PubMed
  145. Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, Anil Yagcioglu AE, Small JG. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2008 Feb; 69(2):274-85.
    View PubMed
  146. Altamura AC, Bobo WV, Meltzer HY. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment. Int Clin Psychopharmacol. 2007 Sep; 22(5):249-67.
    View PubMed
  147. Bobo WV, Warner CH, Warner CM. The management of post traumatic stress disorder (PTSD) in the primary care setting. South Med J. 2007 Aug; 100(8):797-802.
    View PubMed
  148. Warner CH, Rachal J, Breitbach J, Higgins M, Warner C, Bobo W. Current perspectives on chief residents in psychiatry. Acad Psychiatry. 2007 Jul-Aug; 31(4):270-6.
    View PubMed
  149. Warner CH, Bobo W, Warner C, Reid S, Rachal J. Antidepressant discontinuation syndrome. Am Fam Physician. 2006 Aug 1; 74(3):449-56.
    View PubMed
  150. Meltzer HY, Bobo WV. Interpreting the efficacy findings in the CATIE study: what clinicians should know. CNS Spectr. 2006 Jul; 11(7 Suppl 7):14-24.
    View PubMed
  151. Warner CH, Bobo WV, Flynn J. Early career professional development issues for military academic psychiatrists. Acad Psychiatry. 2005 Nov-Dec; 29(5):437-42.
    View PubMed
  152. Keller RT, Greenberg N, Bobo WV, Roberts P, Jones N, Orman DT. Soldier peer mentoring care and support: bringing psychological awareness to the front. Mil Med. 2005 May; 170(5):355-61.
    View PubMed
  153. Bobo WV, Miller SC, Martin B. The abuse liability of dextromethorphan among adolescents: a review. Journal of Child and Adolescent Substance Abuse. 2005; 16(4):55-76.
  154. Bobo WV, Hoge CW, Messina MA, Pavlovcic F, Levandowski D, Grieger T. Characteristics of repeat users of an inpatient psychiatry service at a large military tertiary care hospital. Mil Med. 2004 Aug; 169(8):648-53.
    View PubMed
  155. Bobo WV, Wortham RR, White KD. Post-traumatic stress disorder: a review and clinical update. Federal Practitioner. 2004; 21(3):76-86.
  156. Keller RT, Bobo WV. Handling human remains. Psychiatric Annals. 2004; 33(8):634-640.
  157. Bobo WV, More KF. Potential Association Between Risperidone and Cerebrovascular Events. Prim Care Companion J Clin Psychiatry. 2003 Jun; 5(3):141.
    View PubMed
  158. Alfonzo CA, Bobo WV, Almond MD. Not a usual suspect; rabeprazole therapy presenting as a severe neuropsychiatric illness: case report. Int J Psychiatry Med. 2003; 33(3):311-5.
    View PubMed
  159. Keller RT, Bobo WV. Handling human remains following the terrorist attack on the Pentagon: experiences of 10 uniformed health care workers. Mil Med. 2002 Sep; 167(9 Suppl):8-11.
    View PubMed
  160. Bobo WV, Miller SC. Complicated dual diagnosis: a case for physician involvement in addictions treatment. Int J Psychiatry Med. 2001; 31(2):233-5.
    View PubMed
  161. Slaughter JR, Jain A, Holmes S, Reid JC, Bobo W, Sherrod NB. Panic disorder in hospitalized cancer patients. Psychooncology. 2000 May-Jun; 9(3):253-8.
    View PubMed
  162. Slaughter J, Bobo W, Childers MK. Selective serotonin reuptake inhibitor treatment of post-traumatic Kluver-Bucy syndrome. Brain Inj. 1999 Jan; 13(1):59-62.
    View PubMed
PST-20423372